- Category
- Medium (2023-24)
- Udyam number
- UDYAM-HP-11-0000560

About Brooks Laboratories Limited
Data last updated:
Brooks Laboratories Limited is a public limited company based in Nalagarh, Himachal Pradesh, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 23 January 2002 and has been in existence for over 24 years.
The company is registered with the Registrar of Companies (ROC), Himachal Pradesh, under CIN L24232HP2002PLC000267. Its GSTIN is 02AACCB5316P1ZR (Himachal Pradesh). The company holds 7 GST registrations, of which 5 are active. It is a listed company as per MCA records. Its shares are listed on BSE: 533543 and NSE: BROOKS.
The company has an authorised share capital of ₹30 Cr and a paid-up capital of ₹29.46 Cr. It is led by directors including Jitendrapratap Rambahadur Singh (Whole-Time Director) and Bhushan Singh Rana (Whole-Time Director).
Its last annual general meeting (AGM) was held on 03 September 2026, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Village Kishanpura Nalagarh Road Baddi, Himachal Pradesh, India – 174101.
As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹85.74 Cr, a growth of 3.9% compared to the previous year. For the same year it recorded a net profit of ₹24.3 Cr (net margin 28.3%) and EBITDA of ₹7.07 Cr (EBITDA margin 8.2%). The net worth stands at ₹122.66 Cr (up 25% YoY). Total assets are valued at ₹132.78 Cr (up 24% YoY).
The company has about 304 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Brooks Laboratories. As per MCA filings, the company has open charges of ₹74.08 Cr and satisfied charges of ₹179.36 Cr on record. Court records list 22 cases involving the company, including 10 filed by the company and 12 filed against it; 4 cases are pending. The company has 58 deals on record (55 market trades, 1 funding round, 1 rights issue), with disclosed funding of ₹11.58 Cr; the latest was in May 2026. The company has 12 MSME Form 1 returns on record between 2019 and 2024, listing 699 overdue payments to 238 micro and small suppliers.
Brooks Laboratories Limited is registered as a medium enterprise under the Udyam registration framework (Reg. No. UDYAM-HP-11-0000560). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website brookslabs.net.
Company details
CIN history
Brooks Laboratories has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L24232HP2002PLC000267, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24232HP2002PLC000267 | Current |
| U24232PB2002PLC024910 | Previous |
| L24232PB2002PLC024910 | Previous |
Recognitions & Rankings of Brooks Laboratories
Contact details
Brooks Laboratories Limited's registered office is in Nalagarh, Himachal Pradesh. Its website is brookslabs.net. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered AddressVillage Kishanpura Nalagarh Road Baddi, Himachal Pradesh, India – 174101
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Brooks Laboratories Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Brands
Brooks Laboratories operates one associated brand: Brooks Laboratories. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Manufacturer of pharmaceutical injectables, tablets, and oral suspensions | brookslabs.net |
Business activity
The main business activity of Brooks Laboratories is manufacturing. In detail, this covers manufacture of basic pharmaceutical products and pharmaceutical preparations.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | 21 | Manufacture of basic pharmaceutical products and pharmaceutical preparations |
To see the full business activity and turnover split of Brooks Laboratories Limited, buy the company report.
Financials of Brooks Laboratories Limited
FY 2025-26 filings availableBrooks Laboratories Limited reported revenue of ₹85.74 Cr (up 3.9% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · ConsolidatedRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | 85.74 | 82.56 | 79.49 | 63.20 | 91.18 | 77.25 |
| Revenue growth | +3.9% | +3.9% | +25.8% | -30.7% | +18.0% | - |
| EBITDA | 7.07 | (8.04) | (17.86) | (29.72) | (14.27) | 0.53 |
| EBITDA margin | +8.3% | -9.7% | -22.5% | -47.0% | -15.7% | +0.7% |
| Profit before tax | 24.59 | (9.79) | (19.55) | (38.36) | (23.92) | (8.97) |
| Net profit | 24.30 | (9.99) | (19.59) | (21.25) | (11.44) | (19.31) |
| Net profit margin | +28.3% | -12.1% | -24.6% | -33.6% | -12.6% | -25.0% |
| EPS (₹) | 8.35 | (3.38) | (7.46) | (8.46) | (4.57) | (7.84) |
| Balance sheet | ||||||
| Total assets | 133 | 107 | 72.68 | 82.49 | 162 | 112 |
| Net worth | 123 | 98.11 | 65.59 | 73.95 | 87.49 | 79.15 |
| Total debt | 8.52 | 7.58 | 5.64 | 6.51 | 25.26 | 31.38 |
| Cash & bank | 7.55 | 1.25 | 0.69 | 1.08 | 3.81 | 1.70 |
| Net working capital | 22.01 | 17.24 | 13.29 | 0.49 | 27.43 | 0.69 |
| Cash flow | ||||||
| Cash from operations | 9.29 | 2.63 | (9.80) | (14.49) | (37.44) | 4.46 |
| Cash from investing | (2.92) | (45.14) | 0.18 | 0.49 | (24.91) | (5.13) |
| Cash from financing | 0.17 | 42.43 | 9.72 | 11.41 | 64.07 | 1.16 |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 19.25 | 22.96 | 20.21 | 16.57 | 23.45 | 25.51 | 23.32 | 20.52 |
| Revenue growth (YoY) | -17.9% | -10.0% | -13.3% | -19.3% | +12.8% | +42.3% | - | - |
| Other income | 75.68 | 0.18 | 1.35 | 5.32 | 6.13 | 7.15 | 0.62 | 0.03 |
| EBITDA | (2.06) | (1.34) | 0.68 | 0.74 | 2.52 | 3.12 | (1.25) | (1.49) |
| EBITDA margin | -10.7% | -5.8% | +3.4% | +4.5% | +10.7% | +12.2% | -5.4% | -7.3% |
| Depreciation | 0.45 | 0.42 | 0.41 | 0.39 | 0.39 | 0.39 | 0.39 | 0.38 |
| Interest | 0.25 | 0.21 | 0.09 | 0.16 | 0.28 | 0.30 | 0.26 | 0.28 |
| Profit before tax | 72.92 | (1.79) | 1.53 | 5.51 | 7.98 | 9.58 | (1.28) | (2.12) |
| Tax | 5.32 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.18 | 0.00 |
| Net profit | 67.60 | (1.79) | 1.53 | 5.51 | 7.98 | 9.58 | (1.46) | (2.12) |
| EPS (₹) | 22.95 | (0.61) | 0.52 | 1.87 | 2.71 | 3.25 | (0.54) | (0.82) |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 85.74 | 82.56 | 79.49 | 55.54 | 76.97 | 77.27 | 69.69 |
| Revenue growth | +3.9% | +3.9% | +43.1% | -27.8% | -0.4% | +10.9% | - |
| EBITDA | 7.07 | 4.98 | 3.26 | (5.81) | 1.88 | 0.94 | (3.92) |
| EBITDA margin | +8.3% | +6.0% | +4.1% | -10.5% | +2.4% | +1.2% | -5.6% |
| Profit before tax | 5.81 | 3.23 | 1.57 | (8.18) | 0.67 | (8.44) | (13.51) |
| Net profit | 5.52 | 3.03 | 1.53 | (8.19) | 0.41 | (15.53) | (23.19) |
| Net profit margin | +6.4% | +3.7% | +1.9% | -14.8% | +0.5% | -20.1% | -33.3% |
| EPS (₹) | 1.97 | 1.04 | 0.58 | (3.31) | 0.27 | (6.31) | (9.87) |
| Balance sheet | |||||||
| Total assets | 131 | 124 | 76.63 | 65.31 | 73.11 | 74.37 | 128 |
| Net worth | 121 | 115 | 69.53 | 56.78 | 65.00 | 64.21 | 98.41 |
| Total debt | 8.52 | 7.58 | 5.64 | 6.51 | 5.97 | 8.40 | 27.64 |
| Cash & bank | 7.55 | 1.25 | 0.69 | 1.08 | 1.08 | 0.88 | 1.53 |
| Net working capital | 22.01 | 17.24 | 13.29 | 0.49 | 6.69 | 6.71 | 7.82 |
| Cash flow | |||||||
| Cash from operations | 9.29 | 2.63 | (9.80) | 0.55 | 3.12 | (0.90) | (9.39) |
| Cash from investing | (2.92) | (45.14) | 0.18 | (0.40) | 1.12 | (0.74) | (2.33) |
| Cash from financing | 0.17 | 42.43 | 9.72 | (0.21) | (4.22) | 1.31 | 9.61 |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 19.25 | 22.96 | 20.21 | 16.57 | 23.45 | 25.51 | 23.32 | 20.52 |
| Revenue growth (YoY) | -17.9% | -10.0% | -13.3% | -19.3% | +12.8% | +42.3% | - | - |
| Other income | 75.68 | 0.18 | 0.44 | 0.13 | 0.39 | 0.22 | 0.62 | 0.03 |
| Total expenses | 18.93 | 21.10 | 19.53 | 15.83 | 20.93 | 22.39 | 21.74 | 18.94 |
| EBITDA | 0.32 | 1.86 | 0.68 | 0.74 | 2.52 | 3.12 | 1.58 | 1.58 |
| EBITDA margin | +1.7% | +8.1% | +3.4% | +4.5% | +10.7% | +12.2% | +6.8% | +7.7% |
| Depreciation | 0.45 | 0.42 | 0.41 | 0.39 | 0.39 | 0.39 | 0.39 | 0.38 |
| Interest | 0.25 | 0.21 | 0.09 | 0.16 | 0.28 | 0.30 | 0.26 | 0.28 |
| Profit before tax | 75.30 | 1.41 | 0.62 | 0.32 | 2.24 | 2.65 | 1.55 | 0.95 |
| Tax | 5.32 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.18 | 0.00 |
Financial Statements
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 19.25 | 22.96 | 20.21 | 16.57 | 23.45 | 25.51 | 23.32 | 20.52 |
| Revenue growth (YoY) | -17.9% | -10.0% | -13.3% | -19.3% | +12.8% | +42.3% | - | - |
| Other income | 75.68 | 0.18 | 1.35 | 5.32 | 6.13 | 7.15 | 0.62 | 0.03 |
| EBITDA | (2.06) | (1.34) | 0.68 | 0.74 | 2.52 | 3.12 | (1.25) | (1.49) |
| EBITDA margin | -10.7% | -5.8% | +3.4% | +4.5% | +10.7% | +12.2% | -5.4% | -7.3% |
| Depreciation | 0.45 | 0.42 | 0.41 | 0.39 | 0.39 | 0.39 | 0.39 | 0.38 |
| Interest | 0.25 | 0.21 | 0.09 | 0.16 | 0.28 | 0.30 | 0.26 | 0.28 |
| Profit before tax | 72.92 | (1.79) | 1.53 | 5.51 | 7.98 | 9.58 | (1.28) | (2.12) |
| Tax | 5.32 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.18 | 0.00 |
| Net profit | 67.60 | (1.79) | 1.53 | 5.51 | 7.98 | 9.58 | (1.46) | (2.12) |
| EPS (₹) | 22.95 | (0.61) | 0.52 | 1.87 | 2.71 | 3.25 | (0.54) | (0.82) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Revenue | 85.74 | 82.56 | 79.49 | 63.20 | 91.18 | 77.25 |
| Revenue growth | +3.9% | +3.9% | +25.8% | -30.7% | +18.0% | - |
| Other income | 19.95 | 0.88 | 0.92 | 0.57 | 0.80 | 0.74 |
| Total expenses | 78.67 | 90.60 | 97.35 | 92.92 | 105 | 76.72 |
| Employee cost | 14.62 | 12.45 | 10.09 | 16.00 | 16.85 | 12.04 |
| EBITDA | 7.07 | (8.04) | (17.86) | (29.72) | (14.27) | 0.53 |
| EBITDA margin | +8.3% | -9.7% | -22.5% | -47.0% | -15.7% | +0.7% |
| Depreciation | 1.59 | 1.60 | 1.77 | 7.03 | 7.35 | 7.14 |
| Interest | 0.84 | 1.03 | 0.84 | 2.18 | 3.10 | 3.10 |
| Profit before tax | 24.59 | (9.79) | (19.55) | (38.36) | (23.92) | (8.97) |
| Tax | 0.00 | 0.18 | 0.03 | (7.32) | (4.59) | 10.38 |
| Net profit | 24.30 | (9.99) | (19.59) | (21.25) | (11.44) | (19.31) |
| Net profit margin | +28.3% | -12.1% | -24.6% | -33.6% | -12.6% | -25.0% |
| EPS (₹) | 8.35 | (3.38) | (7.46) | (8.46) | (4.57) | (7.84) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Equity & liabilities | ||||||
| Share capital | 29.46 | 29.46 | 26.25 | 24.70 | 24.70 | 24.70 |
| Reserves & surplus | 93.20 | 68.65 | 39.34 | 49.25 | 62.79 | 54.45 |
| Shareholders' funds (net worth) | 123 | 98.11 | 65.59 | 73.95 | 87.49 | 79.15 |
| Minority interest | 0.00 | 0.00 | 0.00 | 0.00 | 46.83 | 0.00 |
| Secured loans | 7.28 | 6.06 | 5.04 | 5.66 | 24.21 | 31.38 |
| Unsecured loans | 1.24 | 1.52 | 0.60 | 0.85 | 1.05 | 0.00 |
| Total debt | 8.52 | 7.58 | 5.64 | 6.51 | 25.26 | 31.38 |
| Total liabilities | 133 | 107 | 72.68 | 82.49 | 162 | 112 |
| Assets | ||||||
| Gross block | 26.00 | 25.15 | 23.27 | 22.83 | 143 | 133 |
| Net block | 14.52 | 13.98 | 13.67 | 15.00 | 110 | 108 |
| Capital work in progress | 1.19 | 0.00 | 0.00 | 0.00 | 15.11 | 0.83 |
| Investments | 92.34 | 73.55 | 42.91 | 64.03 | 0.06 | 0.02 |
| Inventories | 11.02 | 9.20 | 9.61 | 11.30 | 27.52 | 23.60 |
| Sundry debtors | 16.11 | 19.99 | 16.32 | 12.75 | 17.66 | 13.70 |
| Cash & bank balances | 7.55 | 1.25 | 0.69 | 1.08 | 3.81 | 1.70 |
| Loans & advances | 2.73 | 3.43 | 4.43 | 2.47 | 12.19 | 8.36 |
| Total current assets | 37.41 | 33.87 | 31.05 | 27.60 | 61.18 | 47.36 |
| Total current liabilities | 15.40 | 16.63 | 17.76 | 27.11 | 33.75 | 46.67 |
| Net working capital | 22.01 | 17.24 | 13.29 | 0.49 | 27.43 | 0.69 |
| Total assets | 133 | 107 | 72.68 | 82.49 | 162 | 112 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Opening cash | 0.04 | 0.13 | 0.02 | 2.61 | 0.88 | 0.40 |
| Net cash from operating activities | 9.29 | 2.63 | (9.80) | (14.49) | (37.44) | 4.46 |
| Net cash from investing activities | (2.92) | (45.14) | 0.18 | 0.49 | (24.91) | (5.13) |
| Net cash from financing activities | 0.17 | 42.43 | 9.72 | 11.41 | 64.07 | 1.16 |
| Net change in cash | 6.54 | (0.08) | 0.10 | (2.58) | 1.72 | 0.49 |
| Closing cash | 7.55 | 1.25 | 0.69 | 1.08 | 3.81 | 1.70 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Growth | ||||||
| Sales growth | +3.9% | +3.9% | +25.8% | -30.7% | +18.0% | - |
| EBITDA growth | +187.9% | +55.0% | +39.9% | -108.3% | -2792.5% | - |
| PBT growth | +9998.0% | +49.9% | +49.0% | -60.4% | -166.7% | +9997.0% |
| Net income growth | +343.2% | +49.0% | +7.8% | -85.8% | +40.8% | - |
| Revenue CAGR (3Y) | +10.7% | -3.3% | +1.0% | - | - | - |
| EBITDA CAGR (3Y) | - | -17.4% | - | - | - | - |
| Profitability & leverage | ||||||
| Net income margin | +28.7% | -12.1% | -24.6% | -49.1% | -21.2% | -25.1% |
| Return on capital employed | - | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Return on net worth | - | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Debt / equity | - | 0.08 | 0.09 | 0.20 | 0.40 | 0.40 |
| Long-term debt / equity | - | 0.01 | 0.01 | 0.07 | 0.17 | 0.18 |
| Interest cover | 15.33 | -10.68 | -4.28 | -5.93 | -14.34 | -46.90 |
| Efficiency & per share | ||||||
| Fixed asset turnover | - | 3.41 | 3.45 | 0.76 | 0.66 | 0.58 |
| Inventory turnover | - | 8.78 | 7.60 | 3.26 | 3.56 | 3.27 |
| Debtors turnover | - | 4.55 | 5.47 | 4.16 | 5.81 | 5.64 |
| EPS (₹) | 8.35 | (3.38) | (7.46) | (8.46) | (4.57) | (7.84) |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 41.64 | 33.30 | 24.99 | 29.94 | 35.42 | 32.04 |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 19.25 | 22.96 | 20.21 | 16.57 | 23.45 | 25.51 | 23.32 | 20.52 |
| Revenue growth (YoY) | -17.9% | -10.0% | -13.3% | -19.3% | +12.8% | +42.3% | - | - |
| Other income | 75.68 | 0.18 | 0.44 | 0.13 | 0.39 | 0.22 | 0.62 | 0.03 |
| Total expenses | 18.93 | 21.10 | 19.53 | 15.83 | 20.93 | 22.39 | 21.74 | 18.94 |
| EBITDA | 0.32 | 1.86 | 0.68 | 0.74 | 2.52 | 3.12 | 1.58 | 1.58 |
| EBITDA margin | +1.7% | +8.1% | +3.4% | +4.5% | +10.7% | +12.2% | +6.8% | +7.7% |
| Depreciation | 0.45 | 0.42 | 0.41 | 0.39 | 0.39 | 0.39 | 0.39 | 0.38 |
| Interest | 0.25 | 0.21 | 0.09 | 0.16 | 0.28 | 0.30 | 0.26 | 0.28 |
| Profit before tax | 75.30 | 1.41 | 0.62 | 0.32 | 2.24 | 2.65 | 1.55 | 0.95 |
| Tax | 5.32 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.18 | 0.00 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 85.74 | 82.56 | 79.49 | 55.54 | 76.97 | 77.27 | 69.69 |
| Revenue growth | +3.9% | +3.9% | +43.1% | -27.8% | -0.4% | +10.9% | - |
| Other income | 1.17 | 0.88 | 0.92 | 0.12 | 0.95 | 0.96 | 0.41 |
| Total expenses | 78.67 | 77.58 | 76.23 | 61.35 | 75.09 | 76.33 | 73.61 |
| Employee cost | 14.62 | 12.45 | 10.09 | 10.65 | 10.88 | 12.04 | 11.16 |
| EBITDA | 7.07 | 4.98 | 3.26 | (5.81) | 1.88 | 0.94 | (3.92) |
| EBITDA margin | +8.3% | +6.0% | +4.1% | -10.5% | +2.4% | +1.2% | -5.6% |
| Depreciation | 1.59 | 1.60 | 1.77 | 1.72 | 1.49 | 7.09 | 6.65 |
| Interest | 0.84 | 1.03 | 0.84 | 0.77 | 0.67 | 3.25 | 3.35 |
| Profit before tax | 5.81 | 3.23 | 1.57 | (8.18) | 0.67 | (8.44) | (13.51) |
| Tax | 0.00 | 0.18 | 0.03 | 0.00 | 0.00 | 7.15 | 10.86 |
| Net profit | 5.52 | 3.03 | 1.53 | (8.19) | 0.41 | (15.53) | (23.19) |
| Net profit margin | +6.4% | +3.7% | +1.9% | -14.8% | +0.5% | -20.1% | -33.3% |
| EPS (₹) | 1.97 | 1.04 | 0.58 | (3.31) | 0.27 | (6.31) | (9.87) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 29.46 | 29.46 | 26.25 | 24.70 | 24.70 | 24.70 | 24.70 |
| Reserves & surplus | 91.39 | 85.61 | 43.28 | 32.08 | 40.30 | 39.51 | 73.71 |
| Shareholders' funds (net worth) | 121 | 115 | 69.53 | 56.78 | 65.00 | 64.21 | 98.41 |
| Secured loans | 7.28 | 6.06 | 5.04 | 5.66 | 4.92 | 8.40 | 26.88 |
| Unsecured loans | 1.24 | 1.52 | 0.60 | 0.85 | 1.05 | 0.00 | 0.76 |
| Total debt | 8.52 | 7.58 | 5.64 | 6.51 | 5.97 | 8.40 | 27.64 |
| Total liabilities | 131 | 124 | 76.63 | 65.31 | 73.11 | 74.37 | 128 |
| Assets | |||||||
| Gross block | 26.00 | 25.15 | 23.27 | 22.83 | 21.07 | 19.64 | 133 |
| Net block | 14.52 | 13.98 | 13.67 | 15.00 | 15.14 | 14.96 | 113 |
| Capital work in progress | 1.19 | 0.00 | 0.00 | 0.00 | 1.12 | 0.02 | 0.11 |
| Investments | 90.53 | 90.52 | 46.86 | 46.85 | 46.84 | 46.81 | 0.02 |
| Inventories | 11.02 | 9.20 | 9.61 | 11.30 | 16.59 | 12.38 | 13.77 |
| Sundry debtors | 16.11 | 19.99 | 16.32 | 12.75 | 15.03 | 9.59 | 15.56 |
| Cash & bank balances | 7.55 | 1.25 | 0.69 | 1.08 | 1.08 | 0.88 | 1.53 |
| Loans & advances | 2.73 | 3.43 | 4.43 | 2.47 | 4.34 | 2.49 | 7.05 |
| Total current assets | 37.41 | 33.87 | 31.05 | 27.60 | 37.04 | 25.34 | 37.91 |
| Total current liabilities | 15.40 | 16.63 | 17.76 | 27.11 | 30.35 | 18.63 | 30.09 |
| Net working capital | 22.01 | 17.24 | 13.29 | 0.49 | 6.69 | 6.71 | 7.82 |
| Total assets | 131 | 124 | 76.63 | 65.31 | 73.11 | 74.37 | 128 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 0.04 | 0.13 | 0.02 | 0.08 | 0.06 | 0.40 | 2.50 |
| Net cash from operating activities | 9.29 | 2.63 | (9.80) | 0.55 | 3.12 | (0.90) | (9.39) |
| Net cash from investing activities | (2.92) | (45.14) | 0.18 | (0.40) | 1.12 | (0.74) | (2.33) |
| Net cash from financing activities | 0.17 | 42.43 | 9.72 | (0.21) | (4.22) | 1.31 | 9.61 |
| Net change in cash | 6.54 | (0.08) | 0.10 | (0.06) | 0.02 | (0.33) | (2.10) |
| Closing cash | 7.55 | 1.25 | 0.69 | 1.08 | 1.08 | 0.88 | 1.53 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +3.9% | +3.9% | +43.1% | -27.8% | -0.4% | +10.9% | - |
| EBITDA growth | +42.0% | +52.8% | +156.1% | -409.0% | +100.0% | +124.0% | - |
| PBT growth | +79.9% | +105.7% | +9998.0% | - | +9998.0% | +37.5% | +9.6% |
| Net income growth | +82.2% | +98.0% | +118.7% | -2097.6% | +102.6% | +33.0% | - |
| Revenue CAGR (3Y) | +15.6% | +2.4% | +1.0% | -7.3% | +11.8% | +11.5% | +6.6% |
| EBITDA CAGR (3Y) | - | +38.4% | +51.4% | +14.0% | - | - | - |
| Profitability & leverage | |||||||
| Net income margin | +6.8% | +3.7% | +1.9% | -14.7% | +0.9% | -20.2% | -35.0% |
| Return on capital employed | +4.3% | +3.2% | +2.7% | 0.0% | +1.2% | 0.0% | -7.7% |
| Return on net worth | +4.0% | +2.4% | +1.9% | 0.0% | +0.5% | 0.0% | -24.0% |
| Debt / equity | 0.07 | 0.07 | 0.10 | 0.10 | 0.11 | 0.22 | 0.29 |
| Long-term debt / equity | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 | 0.08 | 0.13 |
| Interest cover | 15.33 | 30.47 | 56.38 | -10.23 | 171.79 | -52.85 | -31.69 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 3.35 | 3.41 | 3.45 | 2.53 | 3.78 | 1.02 | 0.53 |
| Inventory turnover | 8.48 | 8.78 | 7.60 | 3.98 | 5.31 | 5.91 | 5.85 |
| Debtors turnover | 4.75 | 4.55 | 5.47 | 4.00 | 6.25 | 6.14 | 5.17 |
| EPS (₹) | 1.97 | 1.04 | 0.58 | (3.31) | 0.27 | (6.31) | (9.87) |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 41.02 | 39.06 | 26.49 | 22.98 | 26.31 | 25.99 | 39.84 |
To see the full year-wise statements and ratios of Brooks Laboratories Limited, buy the company report.
Board of directors of Brooks Laboratories Limited
Brooks Laboratories has 6 current directors and 21 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Jitendrapratap Rambahadur Singh Also directs: Abridge Speciality Limited | Whole-Time Director | 23 Nov 2022 | 3 Years 11 Months | Current |
| Lalit Mahajan | Director | 07 Aug 2024 | 2 Years 3 Months | Current |
| Usha Singh | Director | 07 Aug 2024 | 2 Years 3 Months | Current |
| Manav Mahajan | Director | 28 Sep 2024 | 2 Years 1 Months | Current |
| Bhushan Singh Rana Also directs: Abridge Speciality Limited | Whole-Time Director | 23 Aug 2023 | 3 Years 2 Months | Current |
| Durga Shankar Maity Also directs: Abridge Speciality Limited | Whole-Time Director | 07 Jul 2023 | 3 Years 4 Months | Current |
Auditor
Brooks Laboratories Limited is audited by DMKH & Co. for the financial year 2025.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| DMKH & Co. | FY 2025 | 116886W |
Shareholding
Shareholding for the quarter ended Sep 2026: promoters hold 52.60%, foreign institutional investors hold 0.00%, domestic institutional investors hold 10.40% and retail and other public shareholders hold 37.00%.
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | |
|---|---|---|---|---|
| Promoters | 52.60% | 52.60% | 52.60% | 52.60% |
| Public | 47.40% | 47.40% | 47.40% | 47.40% |
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 30 Sep 2026 | 101409854 | Yes Bank Limited | ₹48.15 Cr | Open | |
| 21 Sep 2026 | 101408689 | Hdfc Bank Limited | ₹22.4 Lakh | Open | |
| 14 Jul 2026 | 101346700 | Hdfc Bank Limited | ₹12 Cr | Open | |
| 04 May 2026 | 101298868 | Hdfc Bank Limited | ₹24.28 Lakh | Open | |
| 24 Dec 2025 | 101214075 | Hdfc Bank Limited | ₹1.28 Cr | Open |
To see the full charge records of Brooks Laboratories Limited, buy the company report.
Total charge records: 28 View all charges
Deals & funding
Brooks Laboratories Limited has 58 deals on record (55 market trades, 1 funding round, 1 rights issue), with disclosed funding of ₹11.58 Cr; the latest was in May 2026.
Deals on record (5 of 58)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Nov 2024 | Market trade | ₹5.46 Cr | Buyer: One-Up Financial Consultants Pvt Ltd Seller: an individual |
| May 2024 | Market trade | ₹1.28 Cr | Seller: Saravana Global Holdings Limited |
| Apr 2018 | Market trade | ₹1.46 Cr | Buyer: Deepthink Ventures Private Limited Seller: Deepthink Ventures Private Limited |
| Sep 2016 | Market trade | ₹3.35 Cr | Buyer: Shrujay Trading Private Limited , 2 individuals Seller: Shrujay Trading Private Limited , 2 individuals |
| Mar 2016 | Market trade | ₹1.83 Cr | Buyer: KL Enterprises LLP Seller: Mudra Securities |
To see the full deal history of Brooks Laboratories Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Brooks Laboratories Limited has 22 court cases on record: 10 filed by Brooks Laboratories, 12 filed against it. 4 cases are pending and 18 are disposed.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 16 | 9 | 4 |
| High courts | 4 | 1 | 0 |
| Supreme Court | 1 | 1 | 0 |
| NCLT | 1 | 1 | 0 |
Cases on record (5 of 22)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, Khurda, Odisha | Arbitration matter | Filed against the company by M/S Odisha State Medical Corporation Ltd. and Others | Pending |
| District court, Khurda, Odisha | Court case (EXECUITION CASES) | Filed by the company against M/S Odisha State Medical Corporation Limited and Others | Pending |
| District court, GANDHINAGAR, Gujarat | Court case (EXE R) | Filed by the company against M/S Gujarat Medical Services Corporation Ltd. Through Its General Manager and 1 other | Disposed |
| Supreme Court | Court case (1008-Company Law, Mrtp, Trai, Sebi, Idrai & Rbi : Appeals u/s 15 Z of Securities and Exchange Board of India Act, 1992.) | Filed against the company by Blue Print Securities Ltd. 1, Croocked Lane, R. No. 109, 1St Floor ,Kolkata , West Bengal and 20 others | Disposed |
| High Court, ORISSA | Writ petition | Filed by the company against Odisha State Medical Corporation Ltd., and 2 others | Disposed |
To see the full case history of Brooks Laboratories Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
Credit ratings & regulatory alerts
Brooks Laboratories Limited was last rated by Care on 06 Jan 2022.
| Rating agency | Rated on | Rating |
|---|---|---|
| Care | 06 Jan 2022 |
To see the full credit ratings and regulatory alerts of Brooks Laboratories Limited, buy the company report.
MSME payment delays
Brooks Laboratories Limited has 12 MSME Form 1 returns on record between 2019 and 2024, listing 699 overdue payments to 238 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 238)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| Micromeg Enterprises Private Limited | |||
| an individual supplier | |||
| Shamshree Lifesciences Limited | |||
| Mac-Chem Products (India) Private Limited | |||
| Maruti Industries |
To see the full MSME payment records of Brooks Laboratories Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Group structure & subsidiaries
Brooks Laboratories has 1 joint venture and 1 associated company. This group structure data is as of FY 2024. The table lists each entity with its relationship and holding.
Employees & EPFO
Brooks Laboratories Limited has a workforce of 304 employees on its EPFO records as of May 2026, across 1 active EPFO establishment.
Headcount by financial year
| Financial year | Employees (EPFO) |
|---|---|
| FY 2026-27 | 304 |
| FY 2025-26 | |
| FY 2024-25 | |
| FY 2023-24 | |
| FY 2022-23 | |
| FY 2021-22 | |
| FY 2020-21 | |
| FY 2019-20 | |
| FY 2018-19 | |
| FY 2017-18 | |
| FY 2016-17 |
To see the full employee and EPFO history of Brooks Laboratories Limited, buy the company report.
GST
Brooks Laboratories has 7 GST registrations: 5 active and 2 cancelled or inactive. The first 4 active GSTINs are listed below.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 02AACCB5316P1ZR | Himachal Pradesh | Active | 01 Jul 2017 |
| 24AACCB5316P1ZL | Gujarat | Active | 01 Jul 2017 |
| 19AACCB5316P1ZC | West Bengal | Active | 26 Aug 2017 |
| 27AACCB5316P2ZE | Maharashtra | Active | 19 Mar 2021 |
To see the full GST registrations and return filing status of Brooks Laboratories Limited, buy the company report.
Recent activity
Brooks Laboratories Limited has 42 board changes on record since 2002: 24 appointments and 18 cessations. The latest: Sonia Gupta ceased to be Director on 29 Sep 2024.
90 earlier events are in the company report.
News
Frequently asked questions
Brooks Laboratories is an active public limited company based in Nalagarh, Himachal Pradesh, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 23 January 2002 (24+ years old) and is registered under CIN L24232HP2002PLC000267. Listed on BSE: 533543 and NSE: BROOKS.
Brooks Laboratories reported revenue of ₹85.74 Cr for FY 2025-26 (up 3.9% YoY) based on consolidated financials.
Brooks Laboratories has 6 current directors:
- Jitendrapratap Rambahadur Singh - Whole-Time Director
- Bhushan Singh Rana - Whole-Time Director
- Durga Shankar Maity - Whole-Time Director
- Lalit Mahajan - Director
- Usha Singh - Director
- Manav Mahajan - Director
The latest financial statements of Brooks Laboratories on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 03 September 2026. Year-wise statements from 2015 are in the company report.
The GSTIN of Brooks Laboratories is 02AACCB5316P1ZR, registered in Himachal Pradesh. The company has 7 GST registrations in all, of which 5 are active and 2 are cancelled or inactive. Other active GSTINs include 24AACCB5316P1ZL (Gujarat), 19AACCB5316P1ZC (West Bengal), 27AACCB5316P2ZE (Maharashtra).
The CIN (Corporate Identification Number) of Brooks Laboratories is L24232HP2002PLC000267. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Brooks Laboratories is a listed company as per MCA records. Its shares are listed on both BSE (code: 533543) and NSE (symbol: BROOKS).
Brooks Laboratories has 22 court cases on record: 10 filed by the company and 12 filed against it. 4 are pending. Most are in the district courts.
Brooks Laboratories was incorporated on 23 January 2002, making it 24+ years old. It is registered with the Registrar of Companies, Himachal Pradesh.
Brooks Laboratories has 58 deals on record (55 market trades, 1 funding round, 1 rights issue), with disclosed funding of ₹11.58 Cr; the latest was in May 2026.
Sonia Gupta ceased to be Director on 29 Sep 2024. Manav Mahajan was appointed as Director on 28 Sep 2024. Deepak Mahajan ceased to be Director on 07 Aug 2024. Brooks Laboratories has 42 board changes on record in total.

